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..... Photodynamic therapy was studied in dogs with and without posterior fossa glioblastomas, This mode of 
therapy consisted of intravenous administration of Photofrin-II at doses ranging from 0.75 to 4 mg/kg 24 
houl'li prior to laser light irradiation in the posterior fossa. Tissue levels of Photofrin-II were four times greater 
in the tumor than in the surrounding normal brain. Irradiation was performed using 1 hour of 500 mW laser 
light at a wavelength of 630 nm delivered through a fiberoptic catheter directly into the tumor bed via a burr 
hole. All animals receiving a high dose (4 or 2 mg/kg) of Photofrin-II developed serious brain-stem neurotoxicity 
resulting in death or significant residual neurological deficits. A lower dose (0.75 mg/kg) of Photofrin-II 
produced tumor kill without significant permanent brain-stem toxicity in either the control animals or the 
animals with cerebellar brain tumol'li receiving photodynamic therapy, 
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PHOTODYNAMIC therapy (PDT) is a relatively new cancer treatment modality involving adminis-tration of a localized photosensitive dye which, 
upon activation with light, destroys tumor cells.4.6-9.16.29 
Currently, the most common regimen for treating brain 
tumors consists of an intravenous administration of 
Photofrin-II 18 to 72 hours prior to localized photoirra-
diation using laser light at a 630-nm wavelength.22,23. 
26,27 The laser light can then be delivered to the sensitized 
tumor cells by directly inserting a fiberoptic diffuser 
into the tumor mass. 13 Alternatively, the tumor can be 
resected and the resulting cavity irradiated using a fluid-
filled balloon through which the light diffuses.23.41 
Uptake and biodistribution of dihematoporphyrin 
(DHE) and hematoporphyrin derivative (HPD) have 
been investigated in several studies using a variety of 
normal tissues and tumor models. 3,5.10,11,14.15.17,21,24,25,34,40 
For these studies, HPD/DHE was labeled with a ra-
dionucleotide. Tritium-labeled eH) HPD, carbon C4C)-
labeled HPD, indium e 1 I In)-labeled HPD, and copper 
(64Cu)-labeled HPD have been successfully synthesized 
for the purpose of studying preferential uptake/reten-
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tion at different postinjection time intervals for a range 
of doses of the radiolabeled HPD/DHE. Doses ranged 
from 0.5 to 20 mg/kg. Overall, these studies indicated 
that there is preferential uptake and retention of HPD/ 
DHE in tumor cells as compared to normal cells. 
Doses of Photofrin-II and laser light used in PDT have 
varied significantly between clinical study groupS.22.23, 
26,27 In general, the Photofrin-II dose ranged from 0.75 
to 5 mg/kg and the light dose varied between 150 and 
2000 J. Additionally, treatment duration (light expo-
sure) varied between 20 and 60 minutes at a laser pow-
er output of 300 to 2000 m W. 
A number of clinical studies have been published 
updating the use of PDT in human brain tumors.I.IS-20. 
22-24,26-28,32-36 Overall, complications of PDT are with-
in acceptable limits and many malignant gliomas 
showed a response to PDT that translated into pro-
longed survival. 23 However, most of these studies in-
cluded only adults with supratentorial brain tumors. 
There are currently few published cases involving the 
use of PDT to treat tumors in the posterior fossa or 
brain tumors in children. 32 
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The treatment of pediatric brain tumors requires 
special considerations.2,J2I.UJ In children, 60% to 70% 
of brain tumors are located in the posterior fossa. These 
infratentorial neoplasms include astrocytomas, medul-
loblastomas, ependymomas, and brain-stem gliomas. 
The close proximity of these malignant and benign 
childhood brain tumors to the brain stem raises special 
safety concerns for the use of PDT in the posterior 
fossa. We believe that the clinical trials in adults and 
animal studies did not sufficiently address this issue. In 
our preclinical animal study, we specifically investigated 
the safety and efficacy of PDT used in the posterior 
fossa. Our canine glioma model enables us to grow 
malignant tumors in the cerebellum adjacent to the 
brain stem.37- 39 Therefore, our model closely resembles 
a pediatric brain tumor situation and allows us to 
evaluate the use of PDT for patients with posterior 
fossa neoplasms. 
Materials and Methods 
Tumor Cell Culture 
Canine glioma clones were grown in monolayer tis-
sue culture in PlOO tissue culture dishes at 3rC in a 
humid 5% to 10% CO2 atmosphere, as previously de-
scribed.37- 39 Cultures were harvested by gently dislodg-
ing the cells from their substratum with a Pasteur pi-
pette, and cell suspensions of approximately 10 million 
cells/0.5 cc were inoculated into each dog. 
Brain Tumor InocuLation 
Adult mongrel dogs, each weighing approximately 
20 kg, were anesthetized with either general barbiturates 
or halothane/nitrous oxide inhalation, and placed on 
ventilatory assistance with endotracheal intubation. 
Craniotomies were performed using a posterior cere-
bellar approach under sterile conditions, and canine 
glioma cell suspensions were injected via a No. 27 
needle through burr holes to a depth of approximately 
I em into either the cerebellar vermis or the left cere-
bellar hemisphere adjacent to the brain stem under 
direct vision. All tumor-bearing and normal control 
dogs were maintained throughout the study on oral 
cyclosporine (100 mg twice a day), azathioprine (50 mg 
twice a day), and prednisone (20 mg twice a day) to 
prevent rejection of the canine glioma allografts and to 
provide proper controls. Wounds were closed in appro-
priate layers after the application of bone wax, and the 
animals were observed daily for neurological symptoms. 
Magnetic Resonance Imaging 
Magnetic resonance (MR) images were obtained in 
all dogs at about 2 weeks after tumor implantation 
using a 1.5-tesla unit with standard T J- and Trweighted 
and gadolinium-enhanced Tj-weighted sequences. Tu-
mor location was confirmed and tumor volumetric 
measurements were made using continuous MR image 
slices.31- 39 All animals were placed under general bar-
biturate anesthesia and received endotracheal intuba-
tion throughout the MR imaging procedures. 
Additional MR images were obtained at I-week in-
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tervals following PDT in order to assess the effects of 
the therapy on the cerebellar tumor and surrounding 
brain, particularly the brain stem. 
Photo/rin Uptake Studies 
Tumor and nontumor brain tissue samples were 
homogenized in a phosphoric acid solution (pH 3.2) to 
determine Photofrin levels. 30 The homogenate was ex-
tracted with chloroform and methanol. Water and pro-
tein layers were discarded while the chloroform layer 
was evaporated to dryness with N2 at 45°C. The Pho-
tofrin residue was resuspended in 1.0 N HCI by soni-
cation and transferred to a tube containing tetrahydro-
furan. The solution was mixed and heated to lOOT for 
30 minutes. The acid hydrolysate was allowed to return 
to room temperature and was then neutralized with 10 
N NaOH, 1 M KH2P04, and 100 mM cetyltrimethyl-
ammonium bromide (pH 7.0). Photofrin fluorescence 
measurements were obtained at an excitation wave-
length of 410 nm and an emission wavelength of 638 
nm. Results are expressed as ng Photofrin-II/mg brain 
tissue as compared to the standard curve of known 
Photofrin-II concentrations prepared using known spik-
ing doses of Photofrin-II added to the tissue sample 
being tested. 
Drug and Light Dosimetry 
Photodynamic therapy was administered to dogs with 
and without tumors at 2 weeks after tumor inoculation. 
All animals received Photofrin-II* 24 hours prior to 
laser light exposure. Photofrin-II was dissolved in 5% 
dextrose and administered intravenously. The dogs 
without tumors were given 4, 2, or 0.75 mg/kg of 
Photofrin-II prior to surgery. Laser power at the tip of 
the fiber ranged from 300 to 800 mW. Treatment time 
varied between 20 and 60 minutes, thus the total light 
dose ranged accordingly between 960 and 1800 J. Once 
it became clear that the dogs receiving 4 or 2 mg/kg of 
Photofrin-II developed severe, usually fatal brain-stem 
neurological deficits, thereafter all dogs received the 
lower dose of 0.75 mg/kg (Table I). 
The dogs with brain tumors received the safer Pho-
tofrin-II dose of 0.75 mg/kg. The total light dose was 
always 1800 J. Treatment time ranged from 60 to 120 
minutes and the laser power at the tip of the fiber from 
250 to 500 mW. Control dogs received either no PDT, 
laser light treatment only, or Photofrin-II administra-
tion only (Table I). 
Light Delivery System 
The laser light source was the Aurora/M laser system 
which produces light at a wavelength of 630 nm, veri-
fied periodically with a spectroscope.t The light from 
the laser was delivered to the target tissue via an inter-
stitial spherical diffusion fiber.* 
,. Photofrin-II supplied by Quadra Logic Technologies, Inc" 
Vancouver, British Columbia, Canada. 
t Laser system and spectroscope manufactured by Cooper 
Lasersonics, Inc., Santa Clara, California. 
* Diffusion fiber manufactured by Laser Therapeutics, Inc., 
Buellton, California. 
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FIG. 1. Gross pathology demonstrating brain-stem hem-
orrhage and necrosis in a dog following photodynamic therapy 
with the high dose (4 mgjkg) of Photofrin-II. 
Laser Power Output Monitoring 
Photodynamic therapy was monitored in all cases 
with light dosimetry consisting of: 1) initial determina-
tion of laser output at the tip of the spherical diffusion 
fiberoptic catheter by a photometer; 2) monitoring of 
the intracerebellar light output from this spherical dif-
fusion tip by another adjacent fiberoptic catheter in the 
brain and connected to a photometer throughout sur-
gery; and 3) continued monitoring of the light emanat-
ing from the laser by a fiberoptic catheter connected to 
yet another photometer from which readings were taken 
continuously throughout PDT. The photoirradiation 
by laser was stopped if the laser output fluctuated by 
more than 10%, and the laser was recalibrated before 
proceeding with further photoirradiation in the cere-
bellum/cerebellar tumor. 
Photodynamic Therapy Procedure 
Prior to surgery, the laser was calibrated to the ap-
propriate wavelength and power levels as described 
above. All dogs received a general barbiturate or gas 
inhalation anesthesia with endotracheal intubation and 
ventilatory assistance. The dogs were placed, under 
sterile conditions, in a stereotactic head frame that 
allowed access to the posterior skull. A craniotomy was 
performed that exposed either the cerebellar vermis or 
the left cerebellar hemisphere. The interstitial spherical 
diffusion fiber was then inserted at a depth of I cm into 
the cerebellar or the tumor tissue. For the dogs with 
tumors, the previous craniotomy site from the brain 
tumor inoculation was usually enlarged in order to 
directly visualize the tumor. Direct visualization and 
preoperative gadolinium-enhanced TI-weighted MR 
images were used to assure the proper placement of the 
fiberoptic diffuser in the tumor. After PDT, bone wax 
was applied to the craniotomy site and the wound was 
closed. 
Pathological Study 
All animals were sacrificed by intravenous barbitu-
rate overdose when significant neurological deficits de-
veloped, producing discomfort and/or difficulty feed-
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TABLE 1 
Summary of treatment protocols used 
No. of Ph~~~~rin ~:~~ 
Dogs (mg/kg) Dose (J) 
normal dogs/no tumor 
4 4 1800 
2 2 1800 
2 0.75 1800 
o 1800 
tumor-bearing dogs 
3 4 0 





brain-stem hemorrhage, necrosis 
brain-stem hemorrhage, necrosis 
brain stem intact 
brain stem intact 
Photofrin levels 4: 1 tumor:brain: 
died of progressi ve tumor growth 
died of progressive tumor growth 
barbiturate anesthesia death before 
laser light treatment* 
barbiturate anesthesia deaths before 
posttreatment MRI* 
tumor necrosis; brain stem intact 
• Anesthesia technique changed from barbiturate injection to gas 
inhalation. MRI = magnetic resonance imaging. 
ing, or at I-month posttreatment. The dogs' brains were 
fixed in formalin for 1 to 2 weeks and then sliced along 
the coronal plane for gross inspection. Measurements 
were made of the needle/fiberoptic catheter tracks as 
well as tumors and areas of hemorrhage or necrosis. 
Sections were then cut for histopathological study and 
stained with hematoxylin and eosin. 
Statistical Analysis 
This study involved a series of experiments in which 
the toxicity and efficacy of PDT for brain tumors were 
evaluated in the cerebellum and adjacent brain stern. 
The primary outcomes of interest were toxicity and 
tumor volume reduction. Tumor volume measure-
ments were based on MR imaging volumetrics, com-
paring pre-and posttherapy measurements. Posttherapy 
tumor and volumetric measurements were analyzed as 
the percentage reduction from pretherapy measure-
ments. The one-sample t-test was used to determine the 
significance of the tumor reductions. Concurrent con-
trol groups were included in each experiment when 
possible. 
Results 
Tissue Photofrin Levels 
Three dogs with brain tumors were injected with 4 
mg/kg Photofrin-II in order to determine Photofrin-II 
uptake. All dogs showed increased Photofrin levels in 
tumor tissue compared to normal brain tissue; the 
selective retention of Photofrin-II was 4. 1 ± 0.77 (mean 
± standard deviation) times greater in tumor than in 
surrounding normal brain. Published data on injected 
Photofrin doses ranging from 0.5 to 20 mg/kg agree 
with this ratio, with higher uptake in tumor than in 
normal brain tissue. 40 
Photodynamic Therapy of Normal Brains 
Initially, the dogs without tumors were treated with 
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FIG. 2. Magnetic resonance images of a dog wilh a posterior fossa tumor obtained just prior 10 photody-
namic therapy (0.75 mg/kg of Photofrin-lI) (PDT, upper left) , at I week after PDT (upper right), at 2 weeks 
after PDT (lower left) , and at 3 weeks after PDT (lower right) . Note the significant shrinkage of the tumor by 
2 and 3 weeks posttherapy. 
PDT in the cerebellar vermis or left cerebellar hemi-
sphere' after receiving 4 mg/kg of Photofrin-II 24 hours 
before photoirradiation. All of the surviving dogs de-
veloped severe brain-stem neurological deficits consist-
ing of ataxia, feeding difficulties (dysphagia), and res-
piratory instability; in the remaining dogs, immediate 
postoperative death occurred from respiratory insuffi-
ciency, later determined to be the result of brain-stem 
necrosis/hemorrhage (Table I and Fig. I). Brain-stem 
necrosis/hemorrhage and similar neurological deficits 
also occurred in dogs receiving 2 mg/kg Photofrin-II 24 
hours before photoirradiation (Table I). 
Subsequently, all dogs were given the lower dose of 
Photofrin-II (0.75 mg/kg) and developed milder or no 
brain-stem deficits (Table 1). Brain histopathology dem-
onstrated small cystic areas of photodynamic tissue 
destruction at the fiberoptic catheter tip in the cerebel-
lum, completely sparing the brain stem. The dog re-
ceiving photoirradiation only, without Photofrin-II 
administration, showed no histopathological changes 
other than the existence of a fiber track (Table I). 
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All dogs with cerebellar brain tumors documented 
by MR images during the week prior to treatment 
underwent PDT. Four dogs died before completing 
therapy/postoperative MR imaging due to the additive 
respiratory depression produced by barbiturate anesthe-
sia in animals witb posterior fossa tumors; such deaths 
were subsequently prevented by using gas inhalation 
anesthesia. All dogs receiving PDT at the Photofrin-II 
dose of 0.75 mg/kg tolerated the procedure well and 
demonstrated no damage to the brain stem. Magnetic 
resonance images of the brain tumors demonstrated 
large areas of central necrosis the week following PDT 
that were not present prior to PDT (Fig. 2). All pre-
treatment brain tumors were homogeneously gadolin-
ium-enhancing masses on MR images. Subsequent 
MR images demonstrated significant (p < 0.05) mean 
shrinkage of residual ring-enhancing brain tumor tissue 
of 42% ± 8% and 81 % ± 1% by 2 and 3 weeks 
posttherapy, respectively. without regrowth throughout 
the I-month period of post-PDT observation and 
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FIG. 3. Graph showing brain tumor volumes in five dogs, 
calculated from magnetic resonance images obtained just prior 
to photodynamic therapy (PDT, Week 0) and at 1,2, and 3 
weeks after PDT. The tumor volume in each slice was com-
puted using the formula for the volume of an ellipsoid: '/j . .". 
. a . b . c, where a = length/2, b = width/2, and c = depth/ 
2. The total volume of each brain tumor was the sum of the 
volumes of tumor in the slices from each brain. 
weekly neuroimaging (Figs. 2 and 3). Minimal clinical 
neurological deficits occurred in these animals, and in 
many cases the neurological deficits that were caused 
by the brain tumors actually improved following PDT. 
All areas of canine glioma tissue and of hemorrhage! 
necrosis in tumor tissue and normal brain were con-
firmed by histopathology (Figs. 4 and 5). 
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FIG. 4. Photomicrograph of tumor tissue treated with pho· 
todynamic therapy showing that the tumor is replaced by 
macro phages, mononuclear inflammatory cells, and calcifi-
cation. H & E, x 21. 
Control Canine Sludies 
The dogs without tumors receiving laser light treat-
ment only demonstrated no apparent deficits. The an-
imals with tumors receiving laser light treatment only 
or Photofrin-II administration only showed progressive 
neurological deterioration. These animals died within 
2 to 3 weeks after tumor inoculation due to the rapidly 
growing tumor. 
Discussion 
The use of PDT for posterior fossa brain tumors may 
provide an adjuvant form of treatment to our already 
existing armamentarium of surgical resection, chemo-
therapy, and external beam radiation therapy. While 
anecdotal success has been reported in the treatment of 
supratentorial brain tumors in adults, there has been 
no well-controlled clinical study of PDT for brain tu-
mors in any group to date. Nonetheless, this technique 
has appeared promising with many dramatic partial 
FIG. 5. Photomicrograph of untreated tumor tissue showing infiltration into the cerebellum (left) and large 
pleomorphic, occasionally multinucleated tumor cells containing large nuclei, prominent nucleoli, and abun-
dant cytoplasm (right). H & E, x 20 (left) and x 200 (right). 
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and complete responses reported in adult glioblastoma 
patientsY,23,26.27,29 Most patients treated thus far have 
had supratentorial brain tumors, many of which were 
partially resected prior to PDT. In these cases, PDT was 
applied through intracavitary balloon laser photoirra-
diation or the placement of multiple interstitial fiberop-
tic catheters to photo irradiate large areas of tumor bulk. 
With posterior fossa tumors located in close prox-
imity to the brain stem, different issues of safety and 
therapeutic efficacy are raised,2,12,!},31 It is our experi-
ence with the canine glioma model studied here that 
cerebellar brain tumors adjacent to the brain stem 
become clinically significant at sizes much smaller than 
those that are often treated by PDT in adult supraten-
torial locations. Therefore, the intratumoral laser light 
application by spherical diffusion catheter photoirradia-
tion seems more appropriate than surgically creating 
large cavities and irradiating through these balloon or 
multiple fiber techniques. 
Our study indicates that under proper conditions 
PDT can be performed in the posterior fossa of dogs. 
A Photofrin-II dose of 0.75 mg/kg administered 24 
hours prior to photoirradiation with a total light dose 
of 1800 J appears to fulfill this condition. At this dose, 
we were able to eliminate brain tumors without causing 
fatal or permanent brain-stem toxicity. We believe that 
PDT may be a safe and effective treatment modality 
for tumors in the posterior fossa sufficient to be consid-
ered for trials. Conventional treatment with external 
beam radiation has often failed in such patients. There-
fore, our laboratory is currently assessing the toxicity of 
posterior fossa PDT following external beam radiation. 
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